Jeff Yass’s Liminal BioSciences Inc. Common Shares LMNL Stock Holding History

Jeff Yass’s Portfolio LMNL Stock Details LMNL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,133	Closed	-$53.7K	–	13563
2023 Q1	$53.7K	Buy	+14,133	New	+$65.3K	﹤0.01%	11675
2022 Q3	–	Sell	-1,976	Closed	-$10K	–	14460
2022 Q2	$10K	Buy	+1,976	New	+$12.9K	﹤0.01%	12516
2022 Q1	–	Sell	-1,722	Closed	-$19K	–	14301
2021 Q4	$19K	Sell	1,722 -362	-17%	-$5.42K	﹤0.01%	12838
2021 Q3	$48K	Sell	2,084 -2,370	-53%	-$68.3K	﹤0.01%	12365
2021 Q2	$173K	Buy	+4,454	New	+$194K	﹤0.01%	11741

Other funds holding LMNL

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ECM

Estabrook Capital Management New York $739M AUM 31.19% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Jeff Yass's LMNL Position: Q2 2023 in Review

Jeff Yass sold out of Liminal BioSciences Inc. Common Shares (LMNL) in Q2 2023, closing a stake of 14,133 shares — an estimated $53.7K sold.

Jeff Yass first reported a position in LMNL in Q2 2021 and held it in 5 quarters. The position peaked at $173K in Q2 2021. 8 funds tracked by Wall St. Rank hold LMNL as of Q2 2023.

Jeff Yass reported no remaining Liminal BioSciences Inc. Common Shares position as of Q2 2023 after selling out during the quarter.
Jeff Yass sold 14,133 Liminal BioSciences Inc. Common Shares shares in Q2 2023, an estimated $53.7K.
Jeff Yass first reported a position in Liminal BioSciences Inc. Common Shares in Q2 2021 and held it in 5 quarters.
Jeff Yass's Liminal BioSciences Inc. Common Shares position peaked at $173K in Q2 2021.
8 funds tracked by Wall St. Rank held Liminal BioSciences Inc. Common Shares as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.